Amgen's PCSK9 contender lines up for EU nod; Medicago splashes $245M on new plant;

@FierceBiotech: ICYMI: Novo's liraglutide works in diabetes and obesity. How about NASH? More | Follow @FierceBiotech

@JohnCFierce: Got a few personal notes and saw at least 1 Twitter campaign linked to our "Influentials' list. Check out the report. Feature | Follow @JohnCFierce

> The European Medicines Agency's Committee for Medicinal Products for Human Use is slated to weigh in on Amgen's ($AMGN) cholesterol-lowering antibody evolocumab this week. Agenda

> Vaccine developer Medicago is spending $245 million to construct a new manufacturing facility in its native Quebec. News

> DNAtrix has teamed up with Alcyone Lifesciences, planning to use the company's drug delivery technology as it develops a treatment for brain cancer. More

Medical Device News

@FierceMedDev: UPDATED w/ interview: Apollo's minimally invasive intragastric weight-loss balloon shows promise in clinical trial. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Advice for med tech entrepreneurs: Identify your customer and consider stakeholders' incentives carefully. Editor's corner | Follow @VarunSaxena2

@EmilyWFierce: $ILMN filed a patent infringement suit against Ariosa/$RHHBY over prenatal testing tech. Release | Follow @EmilyWFierce

> Silk Road scores FDA approval for less invasive stent system. Story

> NEA startup ClarVista gets $14.5M to gain CE mark for intraocular lens. Article

Pharma News

@FiercePharma: J&J nears $7.5M deal in Risperdal case that could have cost $1.2B. Report | Follow @FiercePharma

@EricPFierce: FDA blesses Baxter saline plant in Spain for shipments to U.S. of 0.9% sodium chloride. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Perrigo will talk tie-up if the price is right, CEO says--but Mylan has a ways to go. Report | Follow @CarlyHFierce

> Can Baxalta deliver on its big growth promises? Baxter says yes. More

> Merck KGaA stumbles in Q1 as MS injectable Rebif falls to oral rivals. Report

> Lechleiter takes up Big Pharma's torch to 'debunk' negative myths. Item

Drug Delivery News

> 'Nanosponges' held in place with a hydrogel absorb toxins in MRSA infections. Story

> Study finds testosterone gels and patches safer than injections. More

> Endo to buy Par Pharma for $8B to bulk up in injectables. Item

> Celyad, formerly Cardio3, files for U.S. IPO worth up to $115 million. Article

> FDA approves pediatric version of Treximet to treat migraines. Report

Pharma Manufacturing News

> Pharmaniaga project in Saudi Arabia stalls but others move forward. More

> Janssen gets Rutgers' help in move to continuous manufacturing. Article

> FDA blesses Baxter saline plant in Spain to produce for U.S. More

> J&J donates $6M to Rutgers, which is helping Janssen move to continuous manufacturing. Story

> AstraZeneca says Sweden getting its new $285M biologics plant. Report

Pharma Asia News

> Wockhardt faces long haul on FDA travails, Business Today says. Story

> India's Zydus Cadila has 10 vaccines in development, set to launch next year. More

> India drug IP laws in spotlight again in local Fresenius Kabi-Pfizer case. Article

> Taiwan recalls batches of injectable sodium chloride made by Y.F. Chemical. Report

> Thailand faces pushback from private hospitals on cost claims. Item

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.